Cell cycle regulatory markers in uterine atypical leiomyoma and leiomyosarcoma: Immunohistochemical study of 68 cases with clinical follow-up

American Journal of Surgical Pathology

Volumn 37, Issue 5, 2013, Pages 634-642

  Mills, Anne M ^a   Ly, Amy ^a   Balzer, Bonnie L ^a   Hendrickson, Michael R ^a   Kempson, Richard L ^a   McKenney, Jesse K ^a   Longacre, Teri A ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

atypical leiomyoma; bizarre leiomyoma; cell cycle markers; cellular leiomyoma; leiomyosarcoma; p16; uterine smooth muscle tumor

Indexed keywords

CELL CYCLE PROTEIN; TUMOR MARKER;

ADULT; AGED; ARTICLE; CELL CYCLE; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; LEIOMYOMA; LEIOMYOSARCOMA; METABOLISM; MIDDLE AGED; PATHOLOGY; UTERUS CANCER;

ADULT; AGED; CELL CYCLE; CELL CYCLE PROTEINS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LEIOMYOMA; LEIOMYOSARCOMA; MIDDLE AGED; TUMOR MARKERS, BIOLOGICAL; UTERINE NEOPLASMS; YOUNG ADULT;

EID: 84876675878     PISSN: 01475185     EISSN: 15320979     Source Type: Journal    
DOI: 10.1097/PAS.0b013e318287779c     Document Type: Article

References (23)

1. Bell SW, Kempson RL, Hendrickson MR. Problematic uterine smooth muscle neoplasms. A clinicopathologic study of 213 cases. Am J Surg Pathol. 1994;18:535-558.
2. Ly A, Mills AM, Balzer BL, et al. Atypical leiomyomas of the uterus: a clinicopathologic study of 51 cases. Am J Surg Pathol. 2013. (In press).
3. Ip PP, Cheung AN, Clement PB. Uterine smooth muscle tumors of uncertain malignant potential (STUMP): a clinicopathologic analysis of 16 cases. Am J Surg Pathol. 2009;33:992-1005.
4. Atkins KA, Arronte N, Darus CJ, et al. The Use of p16 in enhancing the histologic classification of uterine smooth muscle tumors. Am J Surg Pathol. 2008;32:98-102.
5. O'Neill CJ, McBride HA, Connolly LE, et al. Uterine leiomyosar-comas are characterized by high p16, p53 and MIB1 expression in comparison with usual leiomyomas, leiomyoma variants and smooth muscle tumours of uncertain malignant potential. Histo-pathology. 2007;50:851-858.
6. Bodner-Adler B, Bodner K, Czerwenka K, et al. Expression of p16 protein in patients with uterine smooth muscle tumors: an immunohistochemical analysis. Gynecol Oncol. 2005;96:62-66.
7. Lim D, Nucci MR, Gilks B, et al. Interobserver Variability in the Interpretation of Tumor Cell Necrosis in Uterine Leiomyosarcoma. 2013. (In press).
8. Donhuijsen K. Mitosis counts: reproducibility and significance in grading of malignancy. Hum Pathol. 1986;17:1122-1125.
9. Donhuijsen K, Schmidt U, Hirche H, et al. Changes in mitotic rate and cell cycle fractions caused by delayed fixation. Hum Pathol. 1990;21:709-714.
10. Prayson RA, Hart WR. Mitotically active leiomyomas of the uterus. Am J Clin Pathol. 1992;97:14-20.
11. Skubitz KM, Skubitz AP. Differential gene expression in leiomyo-sarcoma. Cancer. 2003;98:1029-1038.
12. Unver NU, Acikalin MF, Oner U, et al. Differential expression of P16 and P21 in benign and malignant uterine smooth muscle tumors. Arch Gynecol Obstet. 2011;284:483-490.
13. Niemann TH, Raab SS, Lenel JC, et al. p53 protein overexpression in smooth muscle tumors of the uterus. Hum Pathol. 1995;26: 375-379.
14. Blom R, Guerrieri C, Stal O, et al. Leiomyosarcoma of the uterus: a clinicopathologic, DNA flow cytometric, p53, and mdm-2 analysis of 49 cases. Gynecol Oncol. 1998;68:54-61.
15. Layfield LJ, Liu K, Dodge R, et al. Uterine smooth muscle tumors: utility of classification by proliferation, ploidy, and prognostic markers versus traditional histopathology. Arch Pathol Lab Med. 2000;124:221-227.
16. Leiser AL, Anderson SE, Nonaka D, et al. Apoptotic and cell cycle regulatory markers in uterine leiomyosarcoma. Gynecol Oncol. 2006;101:86-91.
17. Toyoshima H, Hunter T. p27, a novel inhibitor of G1 cyclin-Cdk protein kinase activity, is related to p21. Cell. 1994;78:67-74.
18. Liu S, Bishop WR, Liu M. Differential effects of cell cycle regulatory protein p21(WAF1/Cip1) on apoptosis and sensitivity to cancer chemotherapy. Drug Resist Updat. 2003;6:183-195.
19. Mayerhofer K, Lozanov P, Bodner K, et al. Ki-67 expression in patients with uterine leiomyomas, uterine smooth muscle tumors of uncertain malignant potential (STUMP) and uterine leio-myosarcomas (LMS). Acta Obstet Gynecol Scand. 2004;83: 1085-1088.
20. Mittal K, Demopoulos RI. MIB-1 (Ki-67), p53, estrogen receptor, and progesterone receptor expression in uterine smooth muscle tumors. Hum Pathol. 2001;32:984-987.
21. Zhai YL, Kobayashi Y, Mori A, et al. Expression of steroid receptors, Ki-67, and p53 in uterine leiomyosarcomas. Int J Gynecol Pathol. 1999;18:20-28.
22. Sun X, Mittal K. MIB-1 (Ki-67), estrogen receptor, progesterone receptor, and p53 expression in atypical cells in uterine symplastic leiomyomas. Int J Gynecol Pathol. 2010;29:51-54.
23. Downes KA, Hart WR. Bizarre leiomyomas of the uterus: a comprehensive pathologic study of 24 cases with long-term follow-up. Am J Surg Pathol. 1997;21:1261-1270.